Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 41,052 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 41,052 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $3.52, for a total transaction of $144,503.04. Following the sale, the chief executive officer now directly owns 3,359,726 shares of the company’s stock, valued at approximately $11,826,235.52. This represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Organogenesis Price Performance

Shares of NASDAQ ORGO traded down $0.18 during trading on Monday, hitting $3.50. The company had a trading volume of 448,089 shares, compared to its average volume of 847,970. The company has a market cap of $464.03 million, a P/E ratio of -58.33 and a beta of 1.73. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The business’s 50-day moving average is $3.37 and its 200 day moving average is $2.97. Organogenesis Holdings Inc. has a 52 week low of $2.16 and a 52 week high of $4.70.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.11. The business had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period in the prior year, the business posted $0.02 earnings per share. Equities research analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its position in shares of Organogenesis by 11.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock valued at $145,000 after acquiring an additional 5,359 shares in the last quarter. CWM LLC raised its stake in Organogenesis by 301.8% during the 2nd quarter. CWM LLC now owns 25,617 shares of the company’s stock valued at $72,000 after purchasing an additional 19,242 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Organogenesis by 309.3% in the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock valued at $11,136,000 after purchasing an additional 3,005,450 shares in the last quarter. Pallas Capital Advisors LLC acquired a new stake in shares of Organogenesis in the second quarter worth $38,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Organogenesis by 9.4% during the second quarter. Bank of New York Mellon Corp now owns 393,798 shares of the company’s stock valued at $1,103,000 after buying an additional 33,990 shares in the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.